



**EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 18<sup>TH</sup> DECEMBER 2019  
AT 12.30pm**

**IN PHARMACY SEMINAR ROOM , PHARMACY DEPARTMENT,  
ROYAL BLACKBURN HOSPITAL**

**PRESENT:**

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL

**IN ATTENDANCE:**

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

**2019/172: APOLOGIES:**

Dr D Gavan (DG)	Consultant Radiologist ELHT
Dr T McKenzie	GP EL CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

**2019/173: DECLARATION OF INTEREST**

None declared – relevant to agenda items.

**2019/174: MINUTES OF OCTOBER MEETING:**

Accepted as a correct record.

**2019/175: MATTERS ARISING:**

**2019/096: New Product Request – Parathyroid hormone (Natpar®)** - NF has confirmed with NHSE that ELHT is registered as a specialist endocrinology centre and can claim for Natpar from NHSE. NF to advise specialists that a local treatment pathway is written to define where Natpar fits and the patients that may benefit.

**Traffic Light: RED**

**2019/106: Hospital Admissions Checklist – Updated** – two minor amendments to checklist to be updated, then can replace current one in use on website.

**2019/131: Treatment of Vitamin B12 Deficiency Draft** – A pathway is currently being developed with Jane Oakey from Path Lab. To be brought to ELMMB when completed.

**2019/143: LMMG Recommendations (From Sept LMMG) - ADHD Shared Care Guideline – updated** - paediatric pharmacist due to raise concerns over lack of compliance with shared care guideline at community paediatric directorate meeting. A suggestion was made that they have a standard letter to send to GPs. Will feed back outcomes of discussion to ELMMB

**2019/163: LSCMMG Recommendations (from Oct LSCMMG) Lithium Shared Care Guideline (updated June)** – LR has fed comments back to LCFT and the target level section is useful in some patients and should remain in document.

**2019/163: LSCMMG Recommendations (from Oct LSCMMG) Liothyronine New Medicine recommendation** – ongoing.

**2019/159: New Product Request – Artesunate Injection** – change from microbiologist recommendation only to consultant and/or microbiology recommendation.

### **2019/176: NEW PRODUCT REQUEST – RIFAXAMIN FOR SMALL INTESTINAL BACTERIAL OVERGROWTH**

Requested by Dr D Lynch, Consultant Gastroenterologist, as a second line option for treating small intestinal bacterial overgrowth in patients who do not tolerate standard therapeutic regimens. ELMMB request that a microbiology opinion is obtained. Concerns were also expressed about how this condition would be diagnosed, the length course proposed and there is no reference to ciprofloxacin which is current second line.

Requestor to be invited to ELMMB to present application, including microbiology advice.

**Resolved: Requestor to be invited to present at future meeting. LR to check if LMMG would review.**

### **2019/177: LSCMMG CONSULTATIONS (for Jan LSCMMG)**

**Octreotide /Lanreotide for GI secretory disorders New Medicine Assessment** – support red for this unlicensed indication

**Oscillating PEP devices for Non-Cystic Fibrosis Bronchiectasis New Medicines Assessment** – support black.

**Oxygen Therapy for treatment of Cluster Headaches New Medicines Assessment** – It is included on NICE headache pathway but concerns expressed over the practicalities of supply.

**Agglomelatine New Medicines Assessment** – repeat request, but evidence is weak, NICE and SMC have not approved, there are concerns over liver toxicity and use in elderly is restricted. Recommend black traffic light.

**Draft Asthma Treatment Guideline for Children** – ELMMB felt it was too long compared with ELHE guideline so suggested a review of ELHE guidance along with the LSCMMG document and bring updated version back to ELMMB in February 2020.

**Resolved: Comments to be sent to LMMG**

## **2019/178: LSCMMG Recommendations (From Nov LSCMMG)**

**Fidaxomycin (Dificlir®) New Medicine Recommendation** – accepted as written for ELHE.  
**Traffic Light: AMBER**

**Stiripentol (Diacomit®) New Medicine Recommendation** – accepted as written for ELHE.  
**Traffic Light: RED**

**Testosterone Shared Care Guideline updated** – it now includes IM injection and is accepted as written for ELHE.

**Guideline for Antihyperglycaemic Therapy in Type 2 Diabetes - updated** – increased cardiovascular events with some preparations added. Concerns over appropriateness of reference to *increased cardiovascular events with some preparations* cost effectiveness information. SR to e-mail the chair of LSCMMG to raise concerns. Guideline not to be adopted locally.

**Rheumatoid Arthritis High Cost drugs Pathway - updated** – format changed to a one page document. Biosimilar brand names to be added and then shared with rheumatologists before accepting locally. Bring back to a future meeting.  
**Action: LR/JV to add biosimilar names and send to rheumatologists for comments.**

**Over The Counter Items that should not be Routinely Prescribed in Primary Care Policy** – Not to be adopted locally. ELHE will continue to use NHS England document.

## **2019/179: FORMULARY UPDATES**

**Acetylcysteine eye gel (Ilube®)** – change from green to amber traffic light.  
**Traffic Light: AMBER**

**EMLA® or Ametop® cream** – required in primary care for taking bloods in children  
Change from red to green traffic light.  
**Traffic Light: GREEN**

**Blood Glucose testing strips and needles** – Following a comprehensive review of devices, strips and needles with specialists and patients the following will be added to the formulary: TEE2+, Contour Plus and GlucoMen Areo 2K test strips and GlucoRx Care Point, Fine Point and Safety Pen needles.

**Collagenase clostridium hystolyticum (Xiapex®)** – discontinued by manufacturer, remove from formulary.

**SloPhyllin®** – discontinued by manufacturer, remove from formulary.

**Hyloforte® traffic light** – A request was made to change to green from Amber to reduce referrals for dexterity issues. ELMMB did not support this proposal and concerns were expressed about patients being started on this product despite no issues with dexterity. No change to traffic light. Ophthalmology to provide more details if they wish to pursue.  
**Traffic Light remains Amber.**

**Aspirin 75mg Enteric coated** – tablets are now comparable in cost to dispersible tablets. Add to formulary as an option.

**Resolved: Formulary to be updated as above**

## **2019/180: SAFETY NEEDLES**

Proposal to add new more cost-effective brand of safety needles to formulary as above. Some CCG's do not commission safety needles for supply to district / community nurses. LR to investigate the most cost effective options of supply.

**Resolved: LR to investigate most cost-effective options of supply.**

## **2019/181: ELHE: COPD Guideline – update**

NICE guidance has updated the course of prednisolone to 5 days (from 7). Guideline to be updated and uploaded to website.

**Resolved: ELHE: COPD Guideline to be updated with 5 day prednisolone course length.**

## **2019/182: ELHT Adult Antimicrobial Guide**

**Urological surgical prophylaxis** – addition of renal surgical procedures

**Respiratory system – Acute cough, non-pneumonic LRTI, acute COPD exacerbation** – updated in line with NICE

**Gastrointestinal system – Threadworm treatment** - updated

**Resolved: Updates to Adult Antimicrobial Guide acknowledged.**

## **2019/183: TRANSFER OF MEDICINES BETWEEN CARE HOME AND HOSPITAL CHECKLIST**

Discussed at 2019/175 item 2019/106.

## **2019/184: ORAL ANTICOAGULANTS – REPORT ON INCIDENTS**

VG shared this report produced for the trust with ELMMB highlighting the incidents reported with oral anticoagulant use.

## **2019/185: NICE RECOMMENDATIONS (from Nov)**

Pentosan polysulfate sodium for treating bladder pain syndrome [TA610] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

**Traffic Light: RED**

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613) is not recommended as an option by NICE.

**Traffic Light: BLACK**

## **2019/185a: NICE RECOMMENDATIONS (from July)**

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned - Blueteq form required

**Traffic Light: RED**

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Bisphosphonates for treating osteoporosis (TA464) updated

## **2019/186: HIGHLY SPECIALISED TECHNOLOGIES GUIDANCE (from Nov)**

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST 12) is recommended. Acknowledged.

## **2019/187: EARLY ACCESS TO MEDICINES SCHEME (EAMS)**

Isatuximab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma. Acknowledged.

## **STANDING ITEMS**

### **2019/188: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - November 2019**

Minutes acknowledged

### **2019/171: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA FT, D&T MINUTES – November 2019**

Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 15<sup>th</sup> January 2020 12.30pm**, Seminar Room  
3, Learning & Development centre, RBH

**2020 Meetings** – All on 3<sup>rd</sup> Wednesday of the month at 12.30pm – 2pm

January 15<sup>th</sup>

February 19<sup>th</sup>

March 18<sup>th</sup>

April 15<sup>th</sup>

May 20<sup>th</sup>

June 17<sup>th</sup>

July 15<sup>th</sup>

August 19<sup>th</sup>

September 16<sup>th</sup>

October 21<sup>st</sup>

November 18<sup>th</sup>

December 16<sup>th</sup>

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 18<sup>TH</sup> DECEMBER 2019**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/131</b>	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed	LR/JV	Feb 20
<b>2019/143</b>	<b>ADHD Shared Care Guideline</b> Follow up the compliance with shared care with paediatric pharmacist	VG	Nov 19
<b>2019/163</b>	<b>LSCMMG Recommendations (From Oct LSCMMG) - Liothyronine New Medicine Recommendation</b> – check with endocrinologists if 3 <sup>rd</sup> bullet point in secondary care section can be removed	VG	Dec 19
<b>2019/176</b>	<b>New Product Request – Rifaxamin For Small Intestinal Bacterial Overgrowth</b> – invite requestor to meeting & obtain microbiology opinion. Share with LMMG	CW LR	Feb 20
<b>2019/178</b>	<b>LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated</b> - Add biosimilar brand names and send to rheumatologists for comments	LR / JV	Feb 20